Study for children with first relapse of B-cell ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests new combinations of targeted drugs (inotuzumab ozogamicin and blinatumomab) for children whose B-cell acute lymphoblastic leukemia (ALL) has come back for the first time. It aims to find the best treatment based on how well the leukemia responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 18 years old when first diagnosed with ALL, and under 21 when joining this study.
- The leukemia must be B-cell precursor ALL that has come back for the first time.
- Your child must be treated at a participating hospital and you must give written permission (informed consent).
- Your child cannot be taking part in any other clinical trial that would interfere with this one.
- Depending on the treatment group, your child’s leukemia cells may need to have certain markers (CD19 or CD22) on their surface.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
This Phase 2 study tests a treatment approach for children with high-risk ALL that has returned. It aims to improve outcomes after relapse by using a planned treatment schedule.
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Hear when a new B-Cell Acute Lymphoblastic Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.